Insulin-induced growth hormone responses in patients with prostatic carcinoma.
Insulin-induced pituitary growth hormone (GH) response was studied in 12 patients with prostatic carcinoma. Three patients demonstrated significant abnormal GH release associated with concentrations which remained on a high plateau during the study. The patients subsequently presented clinically with rapidly progressing disease. Such observations are compatible with the viewpoint that abnormally high or low GH levels systemically present, may be associated with a particularly bad clinical prognosis. Further studies will clarify this relationship.
D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality; D000368:Aged; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000401:mortality; D013268:Stimulation, Chemical
D007328:Insulin; D013006:Growth Hormone